Radius Recycling 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 14, 2013
Document and Entity Information	'	'
Entity Registrant Name	'Radius Health, Inc.	'
Entity Central Index Key	'0001428522	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	879,370
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$19,493	$18,653
Marketable securities	10,250	4,000
Prepaid expenses and other current assets	242	2,463
Total current assets	29,985	25,116
Property and equipment, net	91	139
Other assets	45	45
Total assets	30,121	25,300
Current liabilities:	'	'
Accounts payable	2,684	550
Accrued expenses and other current liabilities	22,943	8,740
Current portion of note payable, net of discount	10,837	7,800
Total current liabilities	36,464	17,090
Note payable, net of current portion and discount	4,369	13,005
Warrant liability	2,499	830
Other liabilities	22,186	24,387
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Common stock, $.0001 par value; 100,000,000 shares authorized, 879,370 and 867,204 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	'	'
Accumulated deficit	-260,258	-200,661
Total stockholders' deficit	-260,258	-200,661
Total liabilities, convertible preferred stock and stockholders' deficit	30,121	25,300
Series B Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	43,024	'
Stockholders' deficit:	'	'
Total stockholders' deficit	43,024	'
Series A-1 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	76,987	71,957
Stockholders' deficit:	'	'
Total stockholders' deficit	76,987	71,957
Series A-2 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	92,094	86,714
Stockholders' deficit:	'	'
Total stockholders' deficit	92,094	86,714
Series A-3 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	11,960	11,182
Stockholders' deficit:	'	'
Total stockholders' deficit	11,960	11,182
Series A-4 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	271	271
Stockholders' deficit:	'	'
Total stockholders' deficit	271	271
Series A-5 Convertible Preferred Stock	'	'
Current liabilities:	'	'
Preferred Stock	525	525
Stockholders' deficit:	'	'
Total stockholders' deficit	$525	$525

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	879,370	867,204
Common stock, shares outstanding	879,370	867,204
Series B Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	980,000	980,000
Preferred Stock, shares issued	701,235	0
Preferred Stock, shares outstanding	701,235	0
Series A-1 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	1,000,000	1,000,000
Preferred Stock, shares issued	939,612	939,612
Preferred Stock, shares outstanding	939,612	939,612
Series A-2 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	983,213	983,213
Preferred Stock, shares issued	983,208	983,208
Preferred Stock, shares outstanding	983,208	983,208
Series A-3 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	142,230	142,230
Preferred Stock, shares issued	142,227	142,227
Preferred Stock, shares outstanding	142,227	142,227
Series A-4 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	4,000	4,000
Preferred Stock, shares issued	3,998	3,998
Preferred Stock, shares outstanding	3,998	3,998
Series A-5 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	7,000	7,000
Preferred Stock, shares issued	6,443	6,443
Preferred Stock, shares outstanding	6,443	6,443
Series A-6 Convertible Preferred Stock	'	'
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	800,000	800,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
OPERATING EXPENSES:	'	'	'	'
Research and development	$15,543	$14,173	$49,070	$38,539
General and administrative	1,621	1,918	4,643	6,209
Loss from operations	-17,164	-16,091	-53,713	-44,748
OTHER (EXPENSE) INCOME:	'	'	'	'
Other (expense) income, net	-2,607	-604	7,465	-1,788
Interest income	11	18	27	53
Interest expense	-582	-853	-1,938	-1,880
NET LOSS	-20,342	-17,530	-48,159	-48,363
OTHER COMPREHENSIVE LOSS, NET OF TAX:	'	'	'	'
Unrealized gain from available-for-sale securities	-3	-7	'	-2
COMPREHENSIVE LOSS	-20,345	-17,537	-48,159	-48,365
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 10):	($25,090)	($21,090)	($60,857)	($58,733)
LOSS PER SHARE:	'	'	'	'
Basic (in dollars per share)	($28.53)	($24.53)	($69.77)	($70.76)
Diluted (in dollars per share)	($28.53)	($24.53)	($69.77)	($70.76)
WEIGHTED AVERAGE SHARES:	'	'	'	'
Basic (in shares)	879,370	859,769	872,195	830,068
Diluted (in shares)	879,370	859,769	872,195	830,068

Statements_of_Convertible_Pref

Statements of Convertible Preferred Stock and Stockholders' Deficit (USD $)	Total	Common Stock	Additional Paid-In-Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Series B Convertible Preferred Stock	Series A-1 Convertible Preferred Stock	Series A-2 Convertible Preferred Stock	Series A-3 Convertible Preferred Stock	Series A-4 Convertible Preferred Stock	Series A-5 Convertible Preferred Stock
In Thousands, except Share data, unless otherwise specified	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Balance at Dec. 31, 2012	($200,661)	'	'	'	($200,661)	'	$71,957	$86,714	$11,182	$271	$525
Balance (in shares) at Dec. 31, 2012	'	867,204	'	'	'	'	939,612	983,208	142,227	3,998	6,443
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'	'	'	'	'
Net loss	-48,159	'	'	'	-48,159	'	'	'	'	'	'
Unrealized gain from available-for-sale securities	'	'	'	0	'	'	'	'	'	'	'
Issuance of common stock	13	'	13	'	'	'	'	'	'	'	'
Issuance of common stock (in shares)	'	12,166	'	'	'	'	'	'	'	'	'
Issuance of preferred stock	'	'	'	'	'	41,514	'	'	'	'	'
Issuance of preferred stock (in shares)	'	'	'	'	'	701,235	'	'	'	'	'
Accretion of dividends on preferred stock	-12,698	'	-1,260	'	-11,438	1,510	5,030	5,380	778	'	'
Stock-based compensation expense	1,247	'	1,247	'	'	'	'	'	'	'	'
Balance at Sep. 30, 2013	($260,258)	'	'	'	($260,258)	$43,024	$76,987	$92,094	$11,960	$271	$525
Balance (in shares) at Sep. 30, 2013	'	879,370	'	'	'	701,235	939,612	983,208	142,227	3,998	6,443

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS USED IN OPERATING ACTIVITIES:	'	'
Net loss	($48,159)	($48,363)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	21	33
Amortization of premium (accretion of discount) on short-term investments, net	28	98
Stock-based compensation expense	1,247	1,311
Research and development expense settled in stock	10,568	6,872
Change in fair value of other current assets, warrant liability and other liability	-7,464	1,766
Non-cash interest	307	339
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	1,813	4,437
Other long-term assets	'	35
Accounts payable	2,134	549
Accrued expenses and other current liabilities	9,646	891
Net cash used in operating activities	-29,859	-32,032
CASH FLOWS (USED IN) PROVIDED BY INVESTING ACTIVITIES:	'	'
Proceeds from sale of equipment	'	45
Purchases of marketable securities	-17,070	-18,989
Sales and maturities of marketable securities	10,793	35,714
Net cash (used in) provided by investing activities	-6,277	16,770
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:	'	'
Proceeds from exercise of stock options	13	269
Payments on note payable	-5,907	-2,155
Proceeds from the issuance of preferred stock, net	42,870	'
Proceeds from note payable, net	'	12,469
Net cash provided by financing activities	36,976	10,583
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	840	-4,679
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	18,653	25,128
CASH AND CASH EQUIVALENTS AT END OF PERIOD	19,493	20,449
SUPPLEMENTAL DISCLOSURES:	'	'
Cash paid for interest	1,426	1,311
NON-CASH FINANCING ACTIVITIES:	'	'
Accretion of dividends on preferred stock	12,698	10,370
Fair value of warrants issued	$1,356	$379

Organization

Organization	9 Months Ended
	Sep. 30, 2013
Organization	'
Organization	'
	1. Organization
	Radius Health, Inc. (“Radius” or the “Company”), which was formerly known as MPM Acquisition Corp., is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions. The Company’s lead product candidate, currently in Phase 3 clinical development, is BA058-SC, a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein (“hPTHrP”) for the treatment of osteoporosis. The BA058-SC Phase 3 study began dosing patients in April 2011 and completed enrollment in March 2013. The Company is also developing BA058-TD, a short wear time, transdermal form of BA058 delivered using a microneedle patch technology from 3M Drug Delivery Systems (“3M”).  The Company commenced a Phase 2 clinical study of BA058-TD during the third quarter of 2012 and completed patient visits in August 2013.  The Company received the top-line data from this study during the third quarter of 2013. The Company also has two other product candidates, RAD1901 and RAD140. RAD1901 is a selective estrogen receptor modulator which is in Phase 2 clinical development for the treatment of vasomotor symptoms (hot flashes) in women entering menopause. The Company is also exploring the use of RAD1901 as a potential treatment for breast cancer brain metastasis (“BCBM”).  The Company has conducted a number of preclinical studies which have provided early proof of concept in application to BCBM and is currently reviewing strategic alternatives with respect to the future development of the product for this treatment. RAD140 is a selective androgen receptor modulator which is currently in preclinical development as a potential treatment for age-related muscle loss, frailty, and weight loss associated with cancer cachexia and osteoporosis.
	Pursuant to an Agreement and Plan of Merger (the “Merger Agreement” or the “Merger”) entered into in April 2011 by and among the Company (a public-reporting, Form 10 shell company at the time), RHI Merger Corp., a Delaware corporation and wholly owned subsidiary of the Company (“MergerCo”), and Radius Health, Inc., a privately-held Delaware corporation (“Former Operating Company”), MergerCo merged with and into the Former Operating Company, with the Former Operating Company remaining as the surviving entity and a wholly-owned subsidiary of the Company.  This transaction is herein referred to as the “Merger.” The Merger was effective as of May 17, 2011, upon the filing of a certificate of merger with the Delaware Secretary of State.  Following the Merger on May 17, 2011, the Company’s Board of Directors approved a transaction pursuant to which the Former Operating Company merged with and into the Company, leaving the Company as the surviving corporation (the Short-Form Merger”).  As part of the Short-Form Merger, the Company, then named MPM Acquisition Corp., changed its name to Radius Health, Inc. and assumed the operations of the Former Operating Company.
	The Company is subject to the risks associated with emerging companies with a limited operating history, including dependence on key individuals, a developing business model, market acceptance of the Company’s product candidates, competition for its product candidates, and the continued ability to obtain adequate financing to fund the Company’s future operations. The Company has incurred losses and expects to continue to incur additional losses for the foreseeable future. As of September 30, 2013, the Company had an accumulated deficit of $260.3 million and believes that its cash and cash equivalents and marketable securities at September 30, 2013 are sufficient to fund its operations into the first quarter of 2014.  Accordingly, the Company expects to pursue financing opportunities to address its future capital needs, including the completion of an additional private placement or public offering and other strategic financing alternatives that could include, but are not limited to, partnering or other collaboration agreements. However, there is no guarantee that any of these financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical and clinical trials and obtain approval of any product candidates from the Federal Drug Administration or other regulatory authorities. In addition, the Company could be forced to discontinue product development, reduce or forego sales and marketing efforts, forego attractive business opportunities or discontinue operations entirely.

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies	'
Basis of Presentation and Significant Accounting Policies	'
	2. Basis of Presentation and Significant Accounting Policies
	Basis of Presentation—The accompanying unaudited condensed financial statements and the related disclosures of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included.
	When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2013.
	Subsequent events have been evaluated up to the date of issuance of these financials. For further information, refer to the financial statements and footnotes included in the Company’s audited financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 15, 2013.
	Significant Accounting Policies—The significant accounting policies identified in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2012 relate to accrued clinical expenses, research and development expenses, stock-based compensation and fair value measures. There were no changes to significant accounting policies during the nine months ended September 30, 2013.
	Accounting Standards Updates—In July 2013, the FASB issued Accounting Standards Update No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”).  ASU 2013-11 clarifies guidance and eliminates diversity in practice on the presentation of unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments to ASU 2013-11 are effective for interim and annual fiscal periods beginning after December 15, 2013, with early adoption permitted. The Company does not expect adoption of ASU 2013-11 will have a material impact on its results of operations, financial position, or cash flows.
	Recently Adopted Accounting Standards—In February 2013, FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income (“ASU 2013-02”). Under ASU 2013-02, an entity is required to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The Company adopted ASU 2013-02 on January 1, 2013. Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2013
Marketable Securities	'
Marketable Securities	'
	3. Marketable Securities
	Available-for-sale marketable securities consisted of the following (in thousands):
		September 30, 2013
		Amortized		Gross		Gross
				Unrealized		Unrealized
		Value		Gains		Losses		Fair Value
	Marketable securities:
	Domestic corporate debt securities	$	2,000	$	—	$	—	$	2,000
	Domestic corporate commercial paper	8,250		—		—		8,250
	Total	$	10,250	$	—	$	—	$	10,250
		December 31, 2012
		Amortized		Gross		Gross
				Unrealized		Unrealized
		Value		Gains		Losses		Fair Value
	Marketable securities:
	Domestic corporate commercial paper	$	4,000	—		—		$	4,000
	Total	$	4,000	$	—	$	—	$	4,000
	The Company held one debt security at September 30, 2013 with a fair value of $2.0 million that had been in an unrealized loss position for less than 12 months.  The Company evaluated the security for other-than-temporary impairment based upon quantitative and qualitative factors and determined that the decline in the market value of the security was most likely due to current economic and market conditions.  In addition, the Company believes that it is not more likely than not that it will be required to sell the security and it does not intend to sell it before the recovery of the amortized cost basis.  Based upon the Company’s analysis, it does not consider the investment to be other-than-temporarily impaired as of September 30, 2013.
	The contractual term to maturity of all marketable securities held by the Company as of September 30, 2013 is less than one year.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	4. Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Research costs	$	21,098	$	6,558
	Payroll and employee benefits	647		962
	Professional fees	245		399
	Vacation	95		129
	Interest on notes payable	799		595
	Other	59		97
	Total accrued expenses and other current liabilties	$	22,943	$	8,740

Convertible_Preferred_Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2013
Convertible Preferred Stock	'
Convertible Preferred Stock	'
	5. Convertible Preferred Stock
	On April 23, 2013, the Company entered into a Series B Convertible Preferred Stock and Warrant Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company could raise, at any time on or prior to May 10, 2013, up to approximately $60.0 million through the issuance of (1) up to 980,000 shares of its Series B preferred stock (the “Series B Shares”) and (2) warrants to acquire up to 2,450,000 shares of its common stock with an exercise price of $6.142 per share. On April 23, 2013, the Company consummated a first closing under the Purchase Agreement, whereby in exchange for aggregate proceeds of approximately $43.0 million, it issued 700,098 Series B Shares and warrants to purchase up to a total of 1,750,248 shares of its common stock.  On May 10, 2013, the Company consummated a second closing under the Purchase Agreement, whereby in exchange for aggregate proceeds of approximately $0.1 million, it issued 1,137 Series B Shares and warrants to purchase up to a total of 2,843 shares of its common stock.
	The rights, preferences, and privileges of the Series B convertible preferred stock (“Series B”) and the Series A-1 convertible preferred stock (“Series A-1”), Series A-2 convertible preferred stock (“Series A-2”), Series A-3 convertible preferred stock (“Series A-3”), Series A-4 convertible preferred stock (“Series A-4”), Series A-5 convertible preferred stock (“Series A-5”) and Series A-6 convertible preferred stock (“Series A-6”) (the Series A-1, Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6, collectively, the “Series A Preferred Stock”) as of September 30, 2013, are set forth below.
	Conversion— Each holder of Series B Shares has the right, at their option at any time, to convert any such shares of Series B into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $61.42 by the conversion price (“Series B Optional Conversion”). The conversion price of the Series B as of September 30, 2013 was $6.142 per share (the “Series B Conversion Price”), which represents a conversion ratio of one share of Series B into ten shares of common stock.
	Each holder of Series A-1, Series A-2 and Series A-3 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price (“Optional Conversion”). The original conversion price of the Series A-1, Series A-2 and Series A-3 was $8.142 per share (the “Conversion Price”), which represented a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into ten shares of common stock. The issuance of the Series B Shares and accompanying warrants under the Purchase Agreement resulted in an adjustment to the Conversion Price of the Series A-1, Series A-2 and Series A-3 (the “Anti-Dilution Adjustment”).  As a result of the Anti-Dilution Adjustment, the effective conversion price of each share of Series A-1, Series A-2 and Series A-3 was reduced to $7.627, which represents a conversion ratio of one share of Series A-1, Series A-2 or Series A-3 into 10.675 shares of common stock.
	Each holder of Series A-4, Series A-5 and Series A-6 has the right, at their option at any time, to convert any such shares of preferred stock into such number of fully paid shares of common stock as is determined by dividing the original purchase price of $81.42 by the conversion price. The conversion price of the Series A-4, Series A-5 and Series A-6 as of September 30, 2013 was $8.142 per share, which represents a conversion ratio of one share of Series A-4, Series A-5 or Series A-6 into ten shares of common stock.
	Upon an optional conversion, the holders of the converted Series B and Series A Preferred Stock are entitled to payment of all accrued, whether or not declared, but unpaid dividends in shares of the common stock of the Company at the then effective conversion price.
	Each share of the Series B and Series A Preferred Stock is automatically convertible into fully paid and non-assessable shares of common stock at the applicable conversion price (as described above) in effect upon (1) a vote of the holders of at least 70% of the outstanding shares of Series B, Series A-1, Series A-2 and Series A-3 to convert all shares of Series B and Series A Preferred Stock or (2) the common stock becoming listed for trading on a national stock exchange (“Special Mandatory Conversion”). Upon a Special Mandatory Conversion, all accrued, whether or not declared, but unpaid dividends shall be paid in cash or shares of common stock (calculated based on the then effective conversion price) at the discretion of the Company’s Board of Directors.
	Redemption— Unless redemption is waived by a requisite stockholder vote or consent, the shares of Series B and Series A Preferred Stock are automatically redeemable upon an event of sale of the Company.  The shares of Series B and Series A Preferred Stock are not redeemable at the option of the holder.
	Dividends— Holders of shares of Series B are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series B. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series B are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, holders of shares of Series A-1 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-1. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-1 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B and Series A-1, holders of Series A-2 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-2. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-2 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, Series A-1 and Series A-2, holders of Series A-3 are entitled to receive dividends at a rate of 8% per annum, compounding annually, which accrue on a daily basis commencing on the date of issuance of the shares of Series A-3. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-3 are also entitled to dividends declared or paid on any shares of common stock.
	Without regard to the payment of required dividends to the holders of Series B, Series A-1, Series A-2 and Series A-3, holders of Series A-5 are entitled to receive the Series A-5 Special Accruing Dividend (as defined in the Company’s certificate of incorporation) paid in shares of Series A-6 as described in note 8. Dividends are payable, as accrued, upon liquidation, event of sale and conversion to common stock, as described above. The holders of shares of Series A-5 are also entitled to dividends declared or paid on any shares of common stock.
	Following payment in full of required dividends to the holders of Series B, Series A-1, Series A-2, Series A-3 and Series A-5, holders of Series A-4 and Series A-6 are entitled to receive, when, if and as declared by the Board of Directors, dividends on any shares of Series A-4 Stock or Series A-6 Stock, as the case may be, out of funds legally available for that purpose, at a rate to be determined by the Board of Directors if and when they may so declare any dividend on the Series A-4 Stock or A-6 Stock, as the case may be. Dividends are payable, as accrued, upon liquidation, event of sale, and conversion to common stock, as described above. The holders of shares of Series A-4 and Series A-6 are also entitled to dividends declared or paid on any shares of common stock.
	Dividends on the Company’s preferred stock are payable, at the sole discretion of the Board of Directors, in cash or in shares of the Company’s common stock at the current market price of shares of common stock, when and if declared by the Board of Directors and upon liquidation or an event of sale.  All accrued but unpaid dividends on Series B and Series A Preferred Stock will be paid in cash or shares of common stock, at the then effective Conversion Price of shares of Series B and Series A Preferred Stock, upon a Special Mandatory Conversion (as defined in the Company’s certificate of incorporation). Upon Optional Conversion, dividends are payable in shares of the common stock at the then effective conversion price of shares of preferred stock.
	As of September 30, 2013, the Company had accrued dividends of $1.5 million, $13.3 million, $16.1 million and $2.3 million on Series B, Series A-1, Series A-2 and Series A-3, respectively.
	Voting—The holders of Series B and Series A Preferred Stock are entitled to vote together with the holders of the common stock as one class on an as-if converted basis.  In addition, as long as the shares of Series A-1 are outstanding, the holders of Series A-1, voting as a separate class, have the right to elect two members of the Company’s Board of Directors.
	Liquidation— The shares of Series B rank senior to the Series A-1 and all other classes of Series A Preferred Stock.  The shares of Series A-1 rank senior to all other classes of Series A Preferred Stock. Series A-2 ranks junior to Series A-1 and senior to Series A-3, Series A-4, Series A-5 and Series A-6. Series A-3, Series A-5 and Series A-6 rank equally but junior to Series A-1 and Series A-2 and senior to Series A-4. Series A-4 ranks senior to the Company’s common stock.
	In the event of a liquidation, dissolution, or winding-up of the Company, the holders of Series B are entitled to be paid first out of the assets available for distribution, before any payment is made to the Series A Preferred Stock. Payment to the holders of Series B shall consist of two (2) times the original purchase price of $61.42, plus all accrued but unpaid dividends.  After such distribution to the holders of Series B, the holders of Series A-1 will be entitled to be paid out of the remaining assets available for distribution, before any payment is made to the Series A-2, Series A-3, Series A-4, Series A-5 and Series A-6. Payment to the holders of Series A-1 shall consist of the original purchase price of $81.42, plus all accrued but unpaid dividends. After the distribution to the holders of Series A-1, the holders of Series A-2 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid dividends. After the distribution to the holders Series A-1 and Series A-2, the holders of Series A-3, Series A-5 and Series A-6, will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any accrued but unpaid or declared and unpaid dividends, as appropriate. After the distribution to the holders Series A-1, Series A-2, Series A-3, Series A-5 and Series A-6, the holders of Series A-4 will be entitled to receive an amount per share equal to the original purchase price per share of $81.42, plus any declared and unpaid dividends.  If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series B, the assets will be distributed ratably among the holders of Series B in proportion to their aggregate liquidation preference amounts.   If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-1, the assets will be distributed ratably among the holders of Series A-1 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-2, the assets will be distributed ratably among the holders of Series A-2 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-3, Series A-5 and Series A-6, the assets will be distributed ratably among the holders of Series A-3, Series A-5 and Series A-6 in proportion to their aggregate liquidation preference amounts. If the assets of the Company are insufficient to pay the full preferential amounts to the holders of Series A-4, the assets will be distributed ratably among the holders of Series A-4 in proportion to their aggregate liquidation preference amounts. After all liquidation preference payments have been made to the holders of the Series B and Series A Preferred Stock, the holders of the Series B and Series A-1, Series A-2 and Series A-3 shall participate in the distribution of the remaining assets with the holders of the Company’s common stock on an as-if converted basis.
	In the event of, and simultaneously with, the closing of an event of sale of the Company (as defined in the Company’s Amended Certificate of Incorporation), the Company shall redeem all of the shares of Series B and Series A Preferred Stock then outstanding at the Special Liquidation Price, as defined. If the event of sale involves consideration other than cash, the Special Liquidation Price may be paid with such consideration having a value equal to the Special Liquidation Price. The Special Liquidation Price shall be equal to an amount per share, which would be received by each holder of the Preferred Stock if, in connection with the event of sale, all the consideration paid in exchange for the assets or the shares of capital stock of the Company was actually paid to and received by the Company, and the Company was immediately liquidated thereafter and its assets distributed pursuant to the liquidation terms above.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	6. Fair Value Measurements
	The Company determines the fair values of its financial instruments based upon the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Below are the three levels of inputs that may be used to measure fair value:
	·                                         Level 1—Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	·                                         Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	·                                         Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of September 30, 2013 and December 31, 2012 (in thousands):
		September 30, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Marketable securities:
	Domestic corporate debt securities (1)	$	—		$	2,000	$	—	$	2,000
	Domestic corporate commercial paper (1)	—			8,250		—		8,250
		$	—		$	10,250	$	—	$	10,250
	Liabilities
	Warrant liability (2)	$	—		$	—	$	2,499	$	2,499
	Other liability (2)	—			—		22,186		22,186
	Stock liability (2)						4,830		4,830
		$	—		$	—	$	29,515	$	29,515
		December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets
	Marketable securities:
	Domestic corporate commercial paper (1)	$	—		$	4,000	$	—	$	4,000
	Stock asset (2)	—			—		407		407
		$	—		$	4,000	$	407	$	4,407
	Liabilities
	Warrant liability (2)	$	—		$	—	$	830	$	830
	Other liability (2)	—			—		24,387		24,387
	Stock liability (2)						245		245
		$	—		$	—	$	25,462	$	25,462
	(1)                           Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.  Inputs are obtained from various sources, including market participants, dealers and brokers.
	(2)                        Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below.  Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.
	The stock asset represents the prepaid balance of the research and development expense related to the stock dividends to be issued to Nordic Bioscience Clinical Development VII A/S (“Nordic”) in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) which is being recognized ratably over the estimated per patient treatment period under the three work statements executed with Nordic (the “Nordic Work Statements”) (see note 8). The stock liability represents the accrued balance of the research and development expense related to the stock dividends to be issued to Nordic in shares of Series A-6 (or in shares of common stock if the Company lists its common stock on a national exchange) which is being recognized ratably over the estimated per patient treatment period under the Nordic Work Statements.
	The fair values of the stock asset and stock liability are based upon the fair value of the Series A-6 as determined using PWERM, which considers the value of the Company’s various classes of preferred stock.  The fair value of the Company’s various classes of preferred stock is determined through an analysis of the future values for equity assuming various future outcomes. Accordingly, share value is based upon the probability weighted present value of expected future net cash flows, considering each of the possible future events, discount rate as determined using the capital asset pricing model, as well as the rights and preferences of each share class.
	PWERM is complex as it requires numerous assumptions relating to potential future outcomes of equity.  Accordingly, the valuation of the Company’s stock asset and stock liability is determined using Level 3 inputs.
	The warrant liability represents the liability for the warrants issued to the placement agent in connection with the Company’s Series A-1 financing, to the investors in the Series B financing in April and May 2013, and to the lenders in connection with the Company’s Loan and Security Agreement executed with Oxford Finance LLC and General Electric Capital Corporation in May 2011. The warrant liability is calculated using the Black-Scholes option pricing method. This method of valuation includes using inputs such as the fair value of the Company’s common stock or preferred stock, historical volatility, the term of the warrant and risk free interest rates. The fair value of the Company’s shares of common stock and preferred stock is estimated using PWERM, as described above. Accordingly, the valuation of the warrant liability is determined using Level 3 inputs.
	The other liability represents the liability to issue shares of Series A-6 for services rendered in connection with the Nordic Work Statements. The liability is calculated based upon the number of shares earned by Nordic through the performance of clinical trial services multiplied by the estimated fair value of the Company’s Series A-6 at each reporting date. The estimated fair value of the Series A-6 is determined using PWERM, as described above. Accordingly, the valuation of the other liability is determined using Level 3 inputs.
	As noted above, the Company’s Level 3 fair value measurements related to its stock asset, stock liability, warrant liability and other liability are based upon the fair value of the Company’s common stock and preferred stock. The following table provides quantitative information about the fair value measurement of the Company’s common stock and preferred stock, including significant unobservable inputs:
	Instrument	Valuation		Unobservable Input		Estimate
		Technique
	Preferred Stock	PWERM		· Time until future exit event (years)		· 0.5 — 1.0
				· Probability of BA058 coming to market		· 65% — 75%
				· Discount rate		· 20% — 40%
				· Long-term revenue growth rate (1)		· 2% — 117%
				· Long-term revenue growth rate (2)		· 8% — 75%
				· Long-term pre-tax operating margin (3)		· 13% — 79%
				· Long-term pre-tax operating margin (4)		· 27% — 73%
				· Discount for lack of marketability		· 14% — 42%
		Market Comparable Companies		· Revenue multiple (5)		· 2.9 — 7.5
	(1)         Estimated long-term revenue growth rate in one scenario has the above range and an average of approximately 24% over 16 revenue years.
	(2)         Estimated long-term revenue growth rate in a second scenario has the above range and an average of approximately 22% over 16 revenue years.
	(3)         Estimated long-term pretax operating margin in one scenario has the above range after achieving positive pretax operating margin and an average of approximately 69% for 17 years.
	(4)         Estimated long-term pretax operating margin in a second scenario has the above range after achieving positive pretax operating margin and an average of approximately 59% for 17 years.
	(5)         Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company’s preferred stock.
	As of September 30, 2013, the warrant liability, other liability and stock liability have fair values of $2.5 million, $22.2 million and $4.8 million, respectively. Changes in the significant unobservable inputs used in the fair value measurements of the Company’s common stock and preferred stock in isolation would result in a significantly different fair value measurement of the stock asset, stock liability, warrant liability and other liability. Generally, a change in the assumption used for the probability of successful development is accompanied by a directionally similar change in the assumption used for the long-term revenue growth rate and long-term pre-tax operating margin and estimated fair value measurement of the Company’s common stock and preferred stock.
	The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2012	$	407
	Expense recognized	(313		)
	Additions	86
	Change in fair value	(180		)
	Balance at September 30, 2013	$	—
	The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2012	$	25,462
Additions	11,697
Change in fair value	(7,644		)
Balance at September 30, 2013	$	29,515
Additions represent the value of the asset or liability for additional accrued shares of stock issuable to Nordic for services rendered in connection with the Company’s Phase 3 clinical study of BA058-SC and Phase 2 clinical study of BA058-TD (see note 8), as well as the value of any new warrants issued during the period.
The fair value of the Company’s note payable is determined using current applicable rates for similar instruments as of the balance sheet date. The carrying value of the Company’s note payable approximated its fair value as of September 30, 2013, as the Company’s interest rate is near current market rates. The fair value of the Company’s notes payable was determined using Level 3 inputs.

License_Agreements

License Agreements	9 Months Ended
	Sep. 30, 2013
License Agreements	'
License Agreements	'
	7. License Agreements
	On September 27, 2005, the Company entered into a license agreement (the “Ipsen Agreement”), as amended, with SCRAS S.A.S, a French corporation on behalf of itself and its affiliates (collectively, “Ipsen”). Under the Ipsen Agreement, Ipsen granted to the Company an exclusive right and license under certain Ipsen compound technology and related patents to research, develop, manufacture and commercialize certain compounds and related products in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. With respect to France, if Ipsen exercises its co-marketing and co-promotion rights, then Ipsen may elect to receive a percentage of the aggregate revenue from the sale of products by both parties in France (subject to a mid-double digit percentage cap) and Ipsen shall bear a corresponding percentage of the costs and expenses incurred by both parties with respect to such marketing and promotion efforts in France; Ipsen shall also pay Radius a mid-single digit royalty on Ipsen’s allocable portion of aggregate revenue from the sale of products by both parties in France. BA058 (the Company’s bone growth drug) is subject to the Ipsen Agreement. Ipsen also granted the Company an exclusive right and license under the Ipsen compound technology and related patents to make and have made compounds or product in Japan. Ipsen also granted the Company an exclusive right and license under certain Ipsen formulation technology and related patents solely for purposes of enabling the Company to develop, manufacture and commercialize compounds and products covered by the compound technology license in all countries, except Japan and (subject to certain co-marketing and co-promotion rights retained by Ipsen) France. In consideration for these licenses, the Company made a nonrefundable, non-creditable payment of $250,000 to Ipsen, which was expensed during 2005. The Ipsen Agreement provides for further payments in the range of €10.0 million to €36.0 million ($13.5 million to $48.7 million) to Ipsen upon the achievement of certain development and commercialization milestones specified in the Ipsen Agreement, and for the payment of fixed 5% royalties on net sales of any product by the Company or its sub-licensees on a country-by-country basis until the last to expire of the licensed patents or for a period of 10 years after the first commercial sale in such country of any product that includes the compound licensed from Ipsen or any analog thereof, whichever is longer.
	If the Company sublicenses the rights licensed from Ipsen, then the Company will also be required to pay Ipsen a percentage of certain payments received from such sublicensee (in lieu of milestone payments not achieved at the time of such sublicense). The applicable percentage is in the low double digit range. In addition, if the Company or its sub-licensees commercialize a product that includes a compound discovered by it based on or derived from confidential Ipsen know-how, it will be obligated to pay to Ipsen a fixed low single digit royalty on net sales of such product on a country-by-country basis until the last to expire of its patents that cover such product or for a period of 10 years after the first commercial sale of such product in such country, whichever is longer. In connection with the Ipsen Agreement, the Company recorded less than $0.1 million and $0.1 million in costs during the three months ended September 30, 2013 and 2012, respectively, and $0.2 million and $0.6 million during the nine months ended September 30, 2013 and 2012, respectively, which were incurred by Ipsen and charged to the Company for the manufacture of the clinical supply of the licensed compound.

Research_Agreements

Research Agreements	9 Months Ended
	Sep. 30, 2013
Research Agreements	'
Research Agreements	'
	8. Research Agreements
	BA058-SC Phase 3 Clinical Study—On March 29, 2011, the Company and Nordic entered into a Clinical Trial Services Agreement, a Work Statement NB-1 (the “Work Statement NB-1”) under such Clinical Trial Services Agreement and a related Stock Issuance Agreement, as amended to date (the “Stock Issuance Agreement”). Pursuant to the Work Statement NB-1, Nordic is managing the Phase 3 clinical study (the “Phase 3 Clinical Study”) of BA058-SC and is being compensated for such services in a combination of cash and shares of stock.
	In December 2011, the Company entered into an amendment to the Work Statement NB-1(the “First Amendment”). Pursuant to the original terms of the Work Statement NB-1, the study was to be conducted in 10 countries at a specified number of sites within each country. The terms of the First Amendment (1) provided for two additional countries (the United States and India) in which the study would be conducted, (2) specified a certain number of sites within each such additional country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect the addition of such countries and sites within the study’s parameters. Payments to be made by the Company to Nordic under the First Amendment are denominated in both euros and U.S. dollars and total up to €717,700 ($971,407) and $289,663, respectively, for the 15 additional study sites in India contemplated by the First Amendment and up to €1.2 million ($1.6 million) and $143,369, respectively, for the five additional study sites in the United States contemplated by the First Amendment.
	In June 2012, the Company entered into a second amendment to the Work Statement NB-1(the “Second Amendment”). Pursuant to the original terms of the Work Statement NB-1, as amended by the First Amendment, the study was to be conducted in 12 countries at a specified number of sites within each country. The terms of the Second Amendment (1) increased the overall number of sites by adding sites in Europe, Brazil and Argentina and removing other sites, (2) specified a certain number of sites within each country for the conduct of the study, and (3) amended various terms and provisions of the Work Statement NB-1 to reflect additional services to be provided at existing sites and the addition of the new study sites within the study’s parameters. The Second Amendment also provided that cash payments to Nordic under the Clinical Trial Services Agreement as well as the payment of shares of stock under the related Stock Issuance Agreement will each be reduced by an amount of €11,941 ($16,162) per subject for any subjects enrolled in India or the United States. Such reductions shall be applied in pro rata monthly installments. Payments to be made by the Company to Nordic under the Second Amendment in connection with the additional services provided at existing sites and the conduct of the study at the new study sites are denominated in both euros and U.S. dollars and total of up to €3.7 million ($5.0 million) and $205,540, respectively.
	Pursuant to the Work Statement NB-1, the Company is required to make certain per patient payments denominated in both euros and U.S. dollars for each patient enrolled in the Phase 3 Clinical Study followed by monthly payments for the duration of the study and final payments in two equal euro-denominated installments and two equal U.S. dollar-denominated installments.  Changes to the Clinical Study schedule may alter the timing, but not the aggregate amounts of the payments.
	The Work Statement NB-1, as amended on December 9, 2011 and June 18, 2012, provides for a total of up to approximately €41.2 million ($55.7 million) of euro-denominated payments and a total of up to approximately $3.2 million of U.S. dollar-denominated payments over the course of the Phase 3 Clinical Study.  These payments may be adjusted based upon actual sites opened, work performed or number of patients enrolled.
	Pursuant to the Stock Issuance Agreement, Nordic agreed to purchase the equivalent of €371,864 of Series A-5 Preferred Stock of the Former Operating Company at $8.142 per share, and the Former Operating Company sold 64,430 shares of its Series A-5 Preferred Stock to Nordic on May 17, 2011 for proceeds of $525,154. These shares were exchanged in the Merger for an aggregate of 6,443 shares of the Company’s Series A-5.
	The Stock Issuance Agreement provides that Nordic is entitled to receive quarterly stock dividends, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock has been converted in accordance with its amended certificate of incorporation, having an aggregate value of up to €36.8 million ($49.8 million) (the “Nordic Accruing Dividend”). In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend is determined based upon the estimated period that will be required to complete the Phase 3 Clinical Study. On the last business day of each calendar quarter (each, an “Accrual Date”), beginning with the quarter ended June 30, 2011, the Company has a liability to issue shares of Series A-6 (or common stock, after the conversion of the Company’s preferred stock into common stock) to Nordic that is referred to as the Applicable Quarterly Amount and is equal to €36.8 million ($49.8 million) (subject to adjustment in accordance with the provisions of the Second Amendment for patients enrolled in India and the U.S.) minus the aggregate value of any prior Nordic Accruing Dividend accrued divided by the number of calendar quarters it will take to complete the Phase 3 Clinical Study. To calculate the aggregate number of shares due to Nordic in each calendar quarter, the Company converts the portion of €36.8 million ($49.8 million) to accrue in such calendar quarter into U.S. dollars using the simple average of the exchange rate for buying U.S. dollars with euros for all Mondays in such calendar quarter. The Company then calculates the aggregate number of shares to accrue in such calendar quarter by dividing the U.S. dollar equivalent of the Applicable Quarterly Amount, by the greater of (1) the fair market value as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number.  Such shares due to Nordic will be issued when declared or paid by the Company’s Board of Directors, who are required to do so upon Nordic’s request, or upon an event of sale. As of September 30, 2013, 405,909 shares of Series A-6 were due to Nordic, or, after the automatic conversion into common stock of the Company’s preferred stock, 4,059,090 shares of common stock.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock is being accounted for as a liability in the Company’s condensed balance sheet. As of September 30, 2013, the fair value of the liability is $19.7 million based upon the fair value of the Series A-6 as determined using PWERM (see note 6). Changes in the fair value from the date of accrual to the date of issuance of the shares are recorded as a gain or loss in other (expense) income in the condensed statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-1 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 3 Clinical Study, or a twenty-month period. The Company recorded $7.6 million and $8.5 million of research and development expense during the three months ended September 30, 2013 and 2012, respectively and $25.5 million and $20.3 million during the nine months ended September 30, 2013 and 2012, respectively, for per patient costs incurred for patients that had enrolled in the Phase 3 Clinical Study.
	As of September 30, 2013, in addition to the $19.7 million liability that is reflected in other liabilities on the condensed balance sheet for the Nordic Accruing Dividend, as noted above, the Company has (1) a liability of $4.5 million reflected in accrued expenses and other current liabilities on the condensed balance sheet resulting from services provided by Nordic, which are payable in the form of a stock dividend and (2) a liability of $13.1 million that is reflected in accrued expenses and other current liabilities on the condensed balance sheet resulting from services provided by Nordic, which are payable in cash.
	BA058-SC Phase 3 Clinical Extension Study— In February 2013, the Company entered into a Work Statement NB-3 (the “Work Statement NB-3”) under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to Work Statement NB-3, Nordic will perform an extension study to evaluate six months of standard-of-care osteoporosis management following the completion of the 18-month BA058-SC Phase 3 Clinical Study (the “Extension Study”) and will be compensated for such services in a combination of cash and shares of stock.  Under the terms of a Letter of Intent that the Company entered into with Nordic on October 22, 2012 setting forth the parties’ obligations to negotiate in good faith to enter into Work Statement NB-3, the Company was required to make an initial payment of €806,468 ($1.1 million).
	Payments in cash to be made to Nordic under the Work Statement NB-3 are denominated in both euros and U.S. dollars and total up to €4.5 million ($6.1 million) and $579,495, respectively. In addition, the Company will issue to Nordic, shares of the Company’s Series A-6 having a value of up to €4.5 million ($6.1 million) and $0.3 million, as additional payment for services to be provided under the Work Statement NB-3 and the Services Agreement.
	The Stock Issuance Agreement provides that, beginning with the quarter ended March 31, 2013, Nordic was entitled to receive quarterly stock dividends in connection with services performed under the Work Statement NB-3, payable in shares of Series A-6 or shares of common stock if the Company’s preferred stock has been automatically converted into common stock in accordance with its amended certificate of incorporation, having an aggregate value of up to €4.5 million ($6.1 million) and $0.3 million. In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend related to the Extension Study is determined based upon the estimated period that will be required to complete the Extension Study. On each Accrual Date, beginning with the quarter ended March 31, 2013, the Company will recognize a liability to issue shares of Series A-6 to Nordic that is referred to as the Applicable Quarterly Amount and is equal to €4.5 million ($6.1 million) and $0.3 million minus the aggregate value of any prior Nordic Accruing Dividend related to the Extension Study divided by the number of calendar quarters it will take to complete the Extension Study. The Company calculates the aggregate number of shares of Series A-6 to accrue in such calendar quarter by dividing the Applicable Quarterly Amount, by the greater of (1) the fair value as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic will be issued when declared or paid by the Company’s board of directors, who are required to do so upon Nordic’s request, or upon an event of sale. As of September 30, 2013, 19,329 shares of Series A-6 are due to Nordic in connection with the Extension Study, or after the automatic conversion into common stock of the Company’s preferred stock, 193,290 shares of common stock.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock is being accounted for as a liability in the Company’s condensed balance sheet. As of September 30, 2013, the fair value of the liability is $0.9 million based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the shares are recorded as a gain or loss in other (expense) income in the condensed statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-3 ratably over the estimated per patient treatment period beginning upon enrollment in the Extension Study, or a nine-month period. The Company recorded $1.3 million and $2.6 million of research and development expense during the three and nine months ended September 30, 2013, respectively, for per patient costs incurred for patients that had enrolled in the Extension Study.
	As of September 30, 2013, in addition to the $0.9 million liability that is reflected in other liabilities on the condensed balance sheet that will be settled in shares of stock, as noted above, the Company has (1) a liability of $0.2 million reflected in accrued expenses and other current liabilities on the condensed balance sheet resulting from services provided by Nordic, which are payable in the form of a stock dividend and (2) a liability of $0.7 million that is reflected in accrued expenses and other current liabilities on the condensed balance sheet resulting from services provided by Nordic, which are payable in cash.
	BA058-TD Phase 2 Clinical Study—On July 26, 2012, the Company entered into a Letter of Intent (the “Letter of Intent”) with Nordic, which provides that the Company and Nordic will, subject to compliance by the Company with certain requirements of its Certificate of Incorporation and applicable securities laws, negotiate in good faith to enter into (1) a Work Statement NB-2 (the “Work Statement NB-2”), a draft of which is attached to the Letter of Intent, and (2) an amendment to the Amended and Restated Stock Issuance Agreement.
	In February 2013, the Company executed the final Work Statement NB-2 under the Clinical Trial Services Agreement and the related Stock Issuance Agreement. Pursuant to the Work Statement NB-2, Nordic will provide clinical trial services relating to the Phase 2 Clinical Study and will be compensated for such services in a combination of cash and shares of stock. Payments in cash to be made by the Company to Nordic under the Work Statement NB-2 are denominated in both euros and U.S. dollars and total up to €3.6 million ($4.9 million) and $257,853, respectively. In addition, the Company will issue to Nordic shares of its Series A-6 stock having a value of up to $2.9 million, as additional payment for services to be provided under the Work Statement NB-2 and the Services Agreement.
	The Stock Issuance Agreement provides that Nordic is entitled to receive quarterly stock dividends in connection with services performed under Work Statement NB-2, payable in shares of Series A-6, or shares of common stock if the Company’s preferred stock has been automatically converted in accordance with its amended certificate of incorporation.  In the event Nordic sells the shares of Series A-5 or in the event the shares of Series A-5 are converted into common stock in accordance with the Company’s amended certificate of incorporation, this right to receive the Nordic Accruing Dividend will terminate, but a right to receive an equivalent number of shares of Series A-6 or common stock, as applicable, will remain with Nordic as a contractual right under the Stock Issuance Agreement.
	The Nordic Accruing Dividend related to the Phase 2 Clinical Study is determined based upon the estimated period that will be required to complete the Phase 2 Clinical Study. On each Accrual Date, beginning with the quarter ended December 31, 2012, the Company will recognize a liability to issue shares of Series A-6 to Nordic that is referred to as the Applicable Quarterly Amount and is equal to up to $2.9 million minus the aggregate value of any prior Nordic Accruing Dividend related to the Phase 2 Clinical Study divided by the number of calendar quarters it will take to complete the Phase 2 Clinical Study. The Company calculates the aggregate number of shares of Series A-6 to accrue in such calendar quarter by dividing the Applicable Quarterly Amount, by the greater of (1) the fair value as of the applicable Accrual Date or (2) $8.142 and rounding down the resulting quotient to the nearest whole number. Such shares due to Nordic will be issued when declared or paid by the Company’s board of directors, who are required to do so upon Nordic’s request, or upon an event of sale. As of September 30, 2013, 32,215 shares of Series A-6 are due to Nordic in connection with the Phase 2 Clinical Study, or after the automatic conversion into common stock of the Company’s preferred stock, 322,150 shares of common stock.
	Prior to the issuance of shares of stock to Nordic in satisfaction of the Nordic Accruing Dividend, the liability to issue shares of stock is being accounted for as a liability in the Company’s condensed balance sheet. As of September 30, 2013, the fair value of the liability is $1.6 million based upon the fair value of the Series A-6 as determined using PWERM. Changes in the fair value from the date of accrual to the date of issuance of the shares are recorded as a gain or loss in other (expense) income in the condensed statement of operations.
	The Company recognizes research and development expense for the amounts due to Nordic under the Work Statement NB-2 ratably over the estimated per patient treatment period beginning upon enrollment in the Phase 2 Clinical Study, or a nine-month period. The Company recorded $0.6 million and $0.1 million of research and development expense during the three months ended September 30, 2013 and 2012, respectively, and $4.1 million and $0.1 million during the nine months ended September 30, 2013 and 2012, respectively, for per patient costs incurred for patients that had enrolled in the Phase 2 Clinical Study.  Additionally, the Company recorded approximately $0.9 million of research and development expense associated with the costs incurred for preparatory and other start-up costs to initiate the Phase 2 Clinical Study during the three months ended September 30, 2012.
	As of September 30, 2013, in addition to the $1.6 million liability that is reflected in other liabilities on the condensed balance sheet that will be settled in shares of stock, as noted above, the Company has a liability of $0.5 million that is reflected in accrued expenses and other current liabilities on the condensed balance sheet resulting from services provided by Nordic, which are payable in cash.
	The Company is also responsible for certain pass-through costs in connection with the Phase 3 Clinical Study, Extension Study and Phase 2 Clinical Study. Pass through costs are expensed as incurred or upon delivery. The Company recognized research and development expense of $1.3 million and $0.5 million for pass-through costs during the three months ended September 30, 2013 and 2012, and $3.3 million and $5.4 million for the nine months ended September 30, 2013 and 2012, respectively.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
Stock-Based Compensation	'
	9. Stock-Based Compensation
	A summary of stock option activity during the nine months ended September 30, 2013 is as follows (in thousands, except for per share amounts):
				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2012	3,899		$	3.1
	Granted	—		—
	Exercised	(12	)	1.1
	Cancelled	(13	)	3.22
	Options outstanding at September 30, 2013	3,874		$	3.11	7.32	$	2,355
	Options exercisable at September 30, 2013	2,281		$	2.65	6.71	$	2,239
	Options vested or expected to vest at September 30, 2013	3,732		$	3.08	7.29	$	2,350
	The total grant-date fair value of stock options that vested during the three and nine months ended September 30, 2013 was approximately $0.7 million and $2.3 million, respectively.
	As of September 30, 2013, there was approximately $2.7 million of total unrecognized compensation expense related to unvested employee stock options, which is expected to be recognized over a weighted-average period of approximately two years.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Net Loss Per Share	'
Net Loss Per Share	'
	10. Net Loss Per Share
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(20,342	)	$	(17,530	)	$	(48,159	)	$	(48,363	)
	Accretion of Preferred Stock	(4,748		)	(3,560		)	(12,698		)	(10,370		)
	Loss attributable to common stockholders - basic and diluted	$	(25,090	)	$	(21,090	)	$	(60,857	)	$	(58,733	)
	Denominator:
	Weighted-average number of common shares used in (loss) earnings per share - basic and diluted	879,370			859,769			872,195			830,068
	(Loss) earnings per share - basic and diluted	$	(28.53	)	$	(24.53	)	$	(69.77	)	$	(70.76	)
	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. For the three and nine months ended September 30, 2013 and 2012, all of the Company’s classes of preferred stock, options to purchase common stock and warrants outstanding were assumed to be anti-dilutive as earnings attributable to common stockholders was in a loss position.
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Convertible preferred stock	12,128,879		4,758,216		10,495,608		4,161,270
	Options to purchase common stock	3,875,614		3,934,488		3,888,660		3,887,672
	Warrants	1,768,091		15,000		1,042,276		15,000

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	11. Commitments and Contingencies
	The Company may be exposed, individually or in the aggregate, to certain claims or assessments in the ordinary course of business. In the opinion of management, the outcome of these matters is not likely to have any material effect on the financial position, results of operations, or cash flows of the Company.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events	'
Subsequent Events	'
	12.  Subsequent Events
	On November 11, 2013 (the “Resignation Date”), Michael S. Wyzga resigned as the President and Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company and entered into a Separation and Release Agreement (the “Separation Agreement”) with the Company.  In connection with such resignation, Mr. Wyzga also entered into a letter agreement (the “Advisory Letter”) with the Company pursuant to which Mr. Wyzga will provide transition advisory services for the Company during a period commencing on the Resignation Date and ending up to 6 months thereafter (the “Advisory Period”).
	Pursuant to the Separation Agreement, Mr. Wyzga agreed to a general release of claims and the Company agreed to provide the severance payments contemplated by the terms of the employment letter agreement entered into between the Company and Mr. Wyzga on December 1, 2011, which include payments totaling $500,000 (an amount equal to Mr. Wyzga’s annual base salary as of the Resignation Date) to be made over the 12 month period following the Resignation Date in accordance with the Company’s normal payroll procedures, and payment of continued medical care premiums necessary for Mr. Wyzga to continue to participate in the Company’s group medical plan during such 12 month period.  In addition, Mr. Wyzga is entitled, as part of such severance payments, to his prorated calendar year 2013 discretionary cash performance bonus under the Company’s bonus plan or program applicable to senior executives based on a target bonus amount equal to 50% of Mr. Wyzga’s annualized base salary, but with the actual amount of any such bonus being determined on the basis of the attainment of Company performance metrics and/or individual performance objectives, in each case, as established and approved by the Board in its sole discretion.  Pursuant to the Advisory Letter, the stock options held by Mr. Wyzga to purchase shares of the Company’s common stock will continue to vest while Mr. Wyzga provides services to the Company during the Advisory Period and will remain exercisable for three months following the Advisory Period.
	The Board appointed Andrew J. Fromkin to the Board and as the Company’s President and Chief Executive Officer, effective as of November 12, 2013.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies	'
Recently Adopted Accounting Standards	'
	Recently Adopted Accounting Standards—In February 2013, FASB issued Accounting Standards Update No. 2013-02, Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income (“ASU 2013-02”). Under ASU 2013-02, an entity is required to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. ASU 2013-02 does not change the current requirements for reporting net income or other comprehensive income in the financial statements. The Company adopted ASU 2013-02 on January 1, 2013. Its adoption did not have a material impact on the Company’s results of operations, financial position or cash flows.

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2013
Marketable Securities	'
Schedule of available-for-sale marketable securities	'
	Available-for-sale marketable securities consisted of the following (in thousands):
		September 30, 2013
		Amortized		Gross		Gross
				Unrealized		Unrealized
		Value		Gains		Losses		Fair Value
	Marketable securities:
	Domestic corporate debt securities	$	2,000	$	—	$	—	$	2,000
	Domestic corporate commercial paper	8,250		—		—		8,250
	Total	$	10,250	$	—	$	—	$	10,250
		December 31, 2012
		Amortized		Gross		Gross
				Unrealized		Unrealized
		Value		Gains		Losses		Fair Value
	Marketable securities:
	Domestic corporate commercial paper	$	4,000	—		—		$	4,000
	Total	$	4,000	$	—	$	—	$	4,000

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Expenses and Other Current Liabilities	'
Schedule of accrued expenses and other current liabilities	'
	Accrued expenses and other current liabilities consist of the following (in thousands):
		September 30,		December 31,
		2013		2012
	Research costs	$	21,098	$	6,558
	Payroll and employee benefits	647		962
	Professional fees	245		399
	Vacation	95		129
	Interest on notes payable	799		595
	Other	59		97
	Total accrued expenses and other current liabilties	$	22,943	$	8,740

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Summary of financial instruments measured at fair value on a recurring basis	'
	The following table summarizes the financial instruments measured at fair value on a recurring basis in the accompanying condensed balance sheets as of September 30, 2013 and December 31, 2012 (in thousands):
		September 30, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Marketable securities:
	Domestic corporate debt securities (1)	$	—		$	2,000	$	—	$	2,000
	Domestic corporate commercial paper (1)	—			8,250		—		8,250
		$	—		$	10,250	$	—	$	10,250
	Liabilities
	Warrant liability (2)	$	—		$	—	$	2,499	$	2,499
	Other liability (2)	—			—		22,186		22,186
	Stock liability (2)						4,830		4,830
		$	—		$	—	$	29,515	$	29,515
		December 31, 2012
		Level 1			Level 2		Level 3		Total
	Assets
	Marketable securities:
	Domestic corporate commercial paper (1)	$	—		$	4,000	$	—	$	4,000
	Stock asset (2)	—			—		407		407
		$	—		$	4,000	$	407	$	4,407
	Liabilities
	Warrant liability (2)	$	—		$	—	$	830	$	830
	Other liability (2)	—			—		24,387		24,387
	Stock liability (2)						245		245
		$	—		$	—	$	25,462	$	25,462
	(1)                           Fair value is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.  Inputs are obtained from various sources, including market participants, dealers and brokers.
	(2)                        Fair value is determined using the probability-weighted expected return model (“PWERM”), as discussed below.  Changes in the fair value of the Level 3 assets and liabilities are recorded as other (expense) income in the condensed statement of operations.
Schedule of quantitative information about the Company's Level 3 fair value measurements, including significant unobservable inputs	'
	Instrument	Valuation		Unobservable Input		Estimate
		Technique
	Preferred Stock	PWERM		· Time until future exit event (years)		· 0.5 — 1.0
				· Probability of BA058 coming to market		· 65% — 75%
				· Discount rate		· 20% — 40%
				· Long-term revenue growth rate (1)		· 2% — 117%
				· Long-term revenue growth rate (2)		· 8% — 75%
				· Long-term pre-tax operating margin (3)		· 13% — 79%
				· Long-term pre-tax operating margin (4)		· 27% — 73%
				· Discount for lack of marketability		· 14% — 42%
		Market Comparable Companies		· Revenue multiple (5)		· 2.9 — 7.5
	(1)         Estimated long-term revenue growth rate in one scenario has the above range and an average of approximately 24% over 16 revenue years.
	(2)         Estimated long-term revenue growth rate in a second scenario has the above range and an average of approximately 22% over 16 revenue years.
	(3)         Estimated long-term pretax operating margin in one scenario has the above range after achieving positive pretax operating margin and an average of approximately 69% for 17 years.
	(4)         Estimated long-term pretax operating margin in a second scenario has the above range after achieving positive pretax operating margin and an average of approximately 59% for 17 years.
	(5)         Represents amounts used when the Company has determined that market participants would use such multiples when valuing the Company’s preferred stock.
Roll-forward of fair value of assets determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the assets, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2012	$	407
	Expense recognized	(313		)
	Additions	86
	Change in fair value	(180		)
	Balance at September 30, 2013	$	—
Roll-forward of fair value of liabilities determined by Level 3 inputs	'
	The following table provides a roll-forward of the fair value of the liabilities, where fair value is determined using Level 3 inputs (in thousands):
	Balance at December 31, 2012	$	25,462
	Additions	11,697
	Change in fair value	(7,644		)
	Balance at September 30, 2013	$	29,515

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation	'
Summary of stock option activity	'
	A summary of stock option activity during the nine months ended September 30, 2013 is as follows (in thousands, except for per share amounts):
				Weighted-
				Average		Weighted-
				Exercise		Average
				Price (in		Contractual	Aggregate
				dollars per		Life (in	Intrinsic
		Shares		share)		years)	Value
	Options outstanding at December 31, 2012	3,899		$	3.1
	Granted	—		—
	Exercised	(12	)	1.1
	Cancelled	(13	)	3.22
	Options outstanding at September 30, 2013	3,874		$	3.11	7.32	$	2,355
	Options exercisable at September 30, 2013	2,281		$	2.65	6.71	$	2,239
	Options vested or expected to vest at September 30, 2013	3,732		$	3.08	7.29	$	2,350

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Net Loss Per Share	'
Schedule of basic and diluted net loss per share	'
	Basic and diluted net loss per share is calculated as follows (in thousands, except share and per share numbers):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(20,342	)	$	(17,530	)	$	(48,159	)	$	(48,363	)
	Accretion of Preferred Stock	(4,748		)	(3,560		)	(12,698		)	(10,370		)
	Loss attributable to common stockholders - basic and diluted	$	(25,090	)	$	(21,090	)	$	(60,857	)	$	(58,733	)
	Denominator:
	Weighted-average number of common shares used in (loss) earnings per share - basic and diluted	879,370			859,769			872,195			830,068
	(Loss) earnings per share - basic and diluted	$	(28.53	)	$	(24.53	)	$	(69.77	)	$	(70.76	)
Schedule of potentially dilutive securities excluded from the computation of diluted weighted-average shares outstanding	'
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Convertible preferred stock	12,128,879		4,758,216		10,495,608		4,161,270
	Options to purchase common stock	3,875,614		3,934,488		3,888,660		3,887,672
	Warrants	1,768,091		15,000		1,042,276		15,000

Organization_Details

Organization (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	item
Organization	'	'
Number of product candidates in preclinical development	2	'
Accumulated deficit	$260,258	$200,661

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
	item		Maximum	Domestic corporate debt securities	Domestic corporate commercial paper	Domestic corporate commercial paper
Available-for-sale marketable securities	'	'	'	'	'	'
Marketable securities, Amortized Cost	$10,250,000	$4,000,000	'	$2,000,000	$8,250,000	$4,000,000
Marketable securities, Fair Value	10,250,000	4,000,000	'	2,000,000	8,250,000	4,000,000
Debt securities held in an unrealized loss position for less than 12 months	1	'	'	'	'	'
Fair value of debt securities in an unrealized position for less than 12 months	$2,000,000	'	'	'	'	'
Marketable securities, contractual term to maturity	'	'	'1 year	'	'	'

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities	'	'
Research costs	$21,098	$6,558
Payroll and employee benefits	647	962
Professional fees	245	399
Vacation	95	129
Interest on notes payable	799	595
Other	59	97
Total accrued expenses and other current liabilities	$22,943	$8,740

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

10-May-13

Apr. 23, 2013

Sep. 30, 2013

Sep. 30, 2013

Apr. 23, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

In Millions, except Share data, unless otherwise specified

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series A-1

Series A-1

Series A-2

Series A-2

Series A-3

Series A-3

Series A-4

Series A-4

Series A-5

Series A-5

Series A-6

Series A-6

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Purchase Agreement

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series A Convertible Preferred Stock

Series A-1

Series A-1

Series A-1

Series A-1

Series A-2

Series A-2

Series A-2

Series A-2

Series A-3

Series A-3

Series A-3

Series A-3

Series A-4

Series A-4

Series A-5

Series A-5

Series A-6

Series A-6

item

Minimum

Maximum

item

item

After payment in full of required Series B preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B preferred stockholders

Minimum

After payment in full of required Series B and A-1 preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B and Series A-1 preferred stockholders

Minimum

After payment in full of required Series B, Series A-1 and A-2 preferred dividends

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Minimum

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1, Series A-2 , Series A-3, Series A-5 and Series A-6 preferred stockholders

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Liquidation, dissolution, or winding-up, payments to preferred stockholders after distribution to Series B, Series A-1 and Series A-2 preferred stockholders

Convertible Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount to be raised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued

701,235

0

939,612

939,612

983,208

983,208

142,227

142,227

3,998

3,998

6,443

6,443

0

0

1,137

700,098

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

980,000

980,000

1,000,000

1,000,000

983,213

983,213

142,230

142,230

4,000

4,000

7,000

7,000

800,000

800,000

'

'

'

'

980,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants (in dollars per unit)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.1

43

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for purchase of shares of common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,843

1,750,248

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share of convertible preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$61.42

$61.42

'

'

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

'

$81.42

$81.42

$81.42

$81.42

$81.42

$81.42

Conversion price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.14

'

'

'

$7.63

'

'

'

$7.63

'

'

'

$7.63

'

'

'

$8.14

'

$8.14

'

$8.14

'

Original conversion price per share (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.14

'

'

'

$8.14

'

'

'

$8.14

'

'

'

'

'

'

'

'

'

Original preferred stock conversion ratio (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

10

'

'

'

10

'

'

'

'

'

'

'

'

'

Preferred Stock conversion ratio (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

10.675

'

'

'

10.675

'

'

'

10.675

'

'

'

10

'

10

'

10

'

Percentage of outstanding shares holders vote required for conversion of all shares of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

70.00%

'

'

'

70.00%

'

'

'

70.00%

'

'

'

'

'

'

Dividend rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

8.00%

'

'

'

8.00%

'

'

'

8.00%

'

'

'

'

'

'

'

'

Accrued dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.50

'

'

'

$13.30

'

'

'

$16.10

'

'

'

$2.30

'

'

'

'

'

'

'

'

'

Payments to preferred stockholders as percentage of original purchase price of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of classes of stockholder voting rights, in the aggregate, for preferred stockholders, on an as-if converted basis, together with common stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members of the Company's Board of Directors that can be elected by preferred stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
	item
Liabilities	'	'
Warrant liability	$2,499	$830
Number of work statements executed with the Nordic Work Statements	3	'
Level 3	'	'
Liabilities	'	'
Warrant liability	2,500	'
Other liability	22,200	'
Stock liability	4,800	'
Recurring basis | Level 2	'	'
Assets	'	'
Assets fair value	10,250	4,000
Recurring basis | Level 2 | Domestic corporate debt securities	'	'
Assets	'	'
Marketable securities	2,000	'
Recurring basis | Level 2 | Domestic corporate commercial paper	'	'
Assets	'	'
Marketable securities	8,250	4,000
Recurring basis | Level 3	'	'
Assets	'	'
Stock asset	'	407
Assets fair value	'	407
Liabilities	'	'
Warrant liability	2,499	830
Other liability	22,186	24,387
Stock liability	4,830	245
Total liabilities carried at fair value	29,515	25,462
Recurring basis | Estimated Fair Value	'	'
Assets	'	'
Stock asset	'	407
Assets fair value	10,250	4,407
Liabilities	'	'
Warrant liability	2,499	830
Other liability	22,186	24,387
Stock liability	4,830	245
Total liabilities carried at fair value	29,515	25,462
Recurring basis | Estimated Fair Value | Domestic corporate debt securities	'	'
Assets	'	'
Marketable securities	2,000	'
Recurring basis | Estimated Fair Value | Domestic corporate commercial paper	'	'
Assets	'	'
Marketable securities	$8,250	$4,000

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Significant unobservable inputs	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock	Preferred Stock
				Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs	Significant unobservable inputs
				PWERM	PWERM	PWERM	Market Comparable Companies	Market Comparable Companies
				Minimum	Maximum	Average	Minimum	Maximum
Quantitative information about the Company's Level 3 fair value measurements	'	'	'	'	'	'	'	'
Time until future exit event	'	'	'	'6 months	'1 year	'	'	'
Probability of BA058 coming to market (as a percent)	'	'	'	65.00%	75.00%	'	'	'
Discount rate (as a percent)	'	'	'	20.00%	40.00%	'	'	'
Long-term revenue growth rate under scenario one (as a percent)	'	'	'	2.00%	117.00%	24.00%	'	'
Long-term revenue growth rate under scenario two (as a percent)	'	'	'	8.00%	75.00%	22.00%	'	'
Long-term pretax operating margin under scenario one (as a percent)	'	'	'	13.00%	79.00%	69.00%	'	'
Long-term pretax operating margin under scenario two (as a percent)	'	'	'	27.00%	73.00%	59.00%	'	'
Discount for lack of marketability (as a percent)	'	'	'	14.00%	42.00%	'	'	'
Revenue multiple	'	'	'	'	'	'	2.9	7.5
Revenue years used in calculation of average estimated long-term revenue growth rate under scenario one	'	'	'	'	'	'16 years	'	'
Revenue years used in calculation of average estimated long-term revenue growth rate under scenario two	'	'	'	'	'	'16 years	'	'
Years used in calculation of average estimated long-term pretax operating margin under scenario one	'	'	'	'	'	'17 years	'	'
Years used in calculation of average estimated long-term pretax operating margin under scenario two	'	'	'	'	'	'17 years	'	'
Warrant liability	$2,499	$830	$2,500	'	'	'	'	'
Other liability	'	'	22,200	'	'	'	'	'
Stock liability	'	'	$4,800	'	'	'	'	'

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Roll-forward of the fair value of the assets, where fair value is determined by Level 3 inputs	'
Balance at the beginning of the period	$407
Expense recognized	-313
Additions	86
Change in fair value	-180
Roll-forward of the fair value of the liabilities, where fair value is determined by Level 3 inputs	'
Balance at the beginning of the period	25,462
Additions	11,697
Change in fair value	-7,644
Balance at the end of the period	$29,515

License_Agreements_Details

License Agreements (Details)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2005

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

USD ($)

USD ($)

USD ($)

USD ($)

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

License agreement

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

Ipsen

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Minimum

Minimum

Maximum

Maximum

Sublicense Agreement

USD ($)

EUR (€)

USD ($)

EUR (€)

Minimum

License Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonrefundable, non-creditable payment

'

'

'

'

'

'

'

'

$250,000

'

'

'

'

'

Additional payments to be made upon achievement of certain development and commercialization milestones

'

'

'

'

'

'

'

'

'

13,500,000

10,000,000

48,700,000

36,000,000

'

Royalty rate (as a percent)

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

Period after the date of the first commercial sale of the product for license expiration

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Amount recorded in research and development expense

$15,543,000

$14,173,000

$49,070,000

$38,539,000

$100,000

$100,000

$200,000

$600,000

'

'

'

'

'

'

Research_Agreements_Details

Research Agreements (Details)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Feb. 28, 2013

Feb. 28, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Feb. 28, 2013

Feb. 28, 2013

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

17-May-11

17-May-11

Mar. 29, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Feb. 28, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

USD ($)

USD ($)

USD ($)

USD ($)

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

Clinical Trial Services Agreement

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-SC Phase 3 Extension Clinical Study

Pass-through costs

Pass-through costs

Pass-through costs

Pass-through costs

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

First Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Second Amendment

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Stock Issuance Agreement

Letter of Intent

Letter of Intent

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

USD ($)

USD ($)

USD ($)

USD ($)

item

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Per patient costs for enrolled patients

Nordic

Nordic

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-SC Phase 3 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-TD Phase 2 Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

BA058-SC Phase 3 Extension Clinical Study

USD ($)

EUR (€)

USD ($)

USD ($)

Maximum

Maximum

Series A-6

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

item

United States

United States

United States

India

India

India

item

USD ($)

EUR (€)

Maximum

Maximum

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

Nordic

item

USD ($)

EUR (€)

Maximum

USD ($)

EUR (€)

item

Maximum

Maximum

item

Maximum

Maximum

USD ($)

EUR (€)

Series A-5

Series A-5

Series A-5

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

Series A-6

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Former Operating Company

Former Operating Company

USD ($)

Maximum

Maximum

Minimum

USD ($)

Minimum

USD ($)

Maximum

Maximum

Minimum

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

Research Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries where study was to be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional countries where study will be conducted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional study sites

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of euro-denominated installments

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Final payments, number of U.S dollar-denominated installments

'

'

'

'

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of euro-denominated payments required over the course of Clinical Study

'

'

'

'

$55,700,000

€ 41,200,000

'

'

$4,900,000

€ 3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,100,000

€ 4,500,000

'

'

$1,600,000

€ 1,200,000

'

$971,407

€ 717,700

'

'

'

$5,000,000

€ 3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of U.S. dollar-denominated payments required over the course of Clinical Study

'

'

'

'

3,200,000

'

'

'

257,853

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

579,495

'

'

'

143,369

'

'

289,663

'

'

'

'

205,540

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of shares agreed to be purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

371,864

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price per share of convertible preferred stock (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.14

'

'

'

'

$8.14

'

$8.14

'

'

'

$8.14

'

'

Shares sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

64,430

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

525,154

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares exchanged in the Merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,443

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

'

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,800,000

36,800,000

'

'

'

'

6,100,000

4,500,000

'

'

'

Aggregate U.S. dollar value of quarterly stock dividends, payable in shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

Number of shares due to the counter party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

405,909

'

'

'

32,215

'

19,329

'

'

'

'

'

Number of shares due to the counter party after conversion of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,059,090

'

'

'

322,150

'

193,290

'

'

'

'

'

Fair value of liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,700,000

'

'

'

1,600,000

'

900,000

'

'

'

'

'

Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash

'

'

'

'

'

'

13,100,000

500,000

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amounts reflected in accrued expenses and other current liabilities resulting from services payable in stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

100,000

'

200,000

'

'

'

'

'

Amount of initial payments for Euro-denominated installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

806,468

Period for which research and development expense is recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 months

'

'

'

'9 months

'

'

'9 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

15,543,000

14,173,000

49,070,000

38,539,000

'

'

'

'

'

'

'

'

1,300,000

500,000

3,300,000

5,400,000

'

7,600,000

8,500,000

25,500,000

20,300,000

600,000

100,000

4,100,000

100,000

1,300,000

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in amount of euro-denominated payments required over the course of clinical study

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,162

11,941

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense related to costs incurred for preparatory and other start-up costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Stock option, USD $)	3 Months Ended	9 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Stock option	'	'
Summary of stock option activity - Shares	'	'
Options outstanding at the beginning of the period (in shares)	'	3,899
Exercised (in shares)	'	-12
Cancelled (in shares)	'	-13
Options outstanding at the end of the period (in shares)	3,874	3,874
Options exercisable at the end of the period (in shares)	2,281	2,281
Options vested and expected to vest at the end of the period (in shares)	3,732	3,732
Summary of stock option activity - Weighted-Average Exercise Price (in dollars per share)	'	'
Options outstanding at the beginning of the period (in dollars per share)	'	$3.10
Exercised (in dollars per share)	'	$1.10
Cancelled (in dollars per share)	'	$3.22
Options outstanding at the end of the period (in dollars per share)	$3.11	$3.11
Options exercisable at the end of the period (in dollars per share)	$2.65	$2.65
Options vested and expected to vest at the end of the period (in dollars per share)	$3.08	$3.08
Weighted-Average Contractual Life (In Years)	'	'
Options outstanding at the end of the period	'	'7 years 3 months 25 days
Options exercisable at the end of the period	'	'6 years 8 months 16 days
Options vested and expected to vest at the end of the period	'	'7 years 3 months 14 days
Aggregate Intrinsic Value	'	'
Options outstanding at the end of the period (in dollars)	$2,355,000	$2,355,000
Options exercisable at the end of the period (in dollars)	2,239,000	2,239,000
Options vested and expected to vest at the end of the period (in dollars)	2,350,000	2,350,000
Additional disclosures	'	'
Total grant date fair value of stock options vested	$700,000	$2,300,000

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Summary of stock-based compensation expense	'
Total unrecognized compensation expense	$2.70
Weighted average period over which unrecognized compensation is expected to be recognized	'2 years

Net_Loss_Per_Share_Details

Net Loss Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net loss	($20,342)	($17,530)	($48,159)	($48,363)
Accretion of Preferred Stock	-4,748	-3,560	-12,698	-10,370
Loss attributable to common stockholders - basic and diluted	($25,090)	($21,090)	($60,857)	($58,733)
Denominator:	'	'	'	'
Weighted-average number of common shares used in (loss) earnings per share - basic and diluted	879,370	859,769	872,195	830,068
(Loss) earnings per share - basic and diluted (in dollars per share)	($28.53)	($24.53)	($69.77)	($70.76)

Net_Loss_Per_Share_Details_2

Net Loss Per Share (Details 2)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Convertible preferred stock	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	12,128,879	4,758,216	10,495,608	4,161,270
Options to purchase common stock	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	3,875,614	3,934,488	3,888,660	3,887,672
Warrants	'	'	'	'
Net Loss Per Share	'	'	'	'
Potentially dilutive securities, prior to the use of the treasury stock method, excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive	1,768,091	15,000	1,042,276	15,000

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event, Michael S. Wyzga, USD $)	0 Months Ended
	Nov. 11, 2013
Subsequent Event | Michael S. Wyzga	'
Subsequent Events	'
Advisory period	'6 months
Severance payments	$500,000
Period from resignation date over which severance payments are required to be made	'12 months
Period from resignation date over which medical care premiums are required to be made	'12 months
Cash performance bonus as a percentage of annualized base salary	50.00%
Exercisable period for stock options following the Advisory period	'3 months